Next-generation Cancer Models Updates
Sign up and receive updates once new models become available
As scientists, we are challenged to discover treatments for cancer patients. Yet, the lack of available models relevant to tumor type, disease progression, and population diversity hinders our progress towards rapid advancements in translational medicine. ATCC believes that this can change—that credible cancer models lead to incredible breakthroughs in translational research. To this end, ATCC is dedicated to providing materials and standards for drug screening, cancer immunology, tumor mechanisms, and cancer diagnostics. New models such as organoids, conditionally reprogrammed cells, luciferase reporter labeled cell lines, isogenic CRISPR/Cas9 genome-edited cell lines, and epithelial-mesenchymal transition cell lines are available. Sign up to receive updates about the advance cancer models available for your research.